Study: Eliquis Safer for Deep Vein Clot Patients Than Key Rival
A major clinical trial comparing two of the world's most widely used blood-thinning medications has found that Eliquis (apixaban) is significantly safer for patients with deep vein thrombosis, clots in the deep veins of the body, than the rival drug it was tested against.
The research, published in the prestigious New England Journal of Medicine, found that Eliquis carries a lower risk of dangerous bleeding complications, which are the most feared side effect of anticoagulant therapy.
Why This Matters for Patients
Deep vein thrombosis (DVT) and the related condition pulmonary embolism, where clots travel to the lungs, are significant causes of death and disability worldwide. Blood thinners are the standard treatment, but they all carry the risk of bleeding, which can range from minor bruising to life-threatening internal hemorrhage.
Finding that one drug produces better outcomes than another in a direct comparison is meaningful news for the hundreds of thousands of Canadians currently on anticoagulant therapy, and for their physicians trying to make the best prescribing choices.
The Clinical Details
The trial directly compared Eliquis against another blood thinner across a sample of patients with confirmed deep vein clots. The results showed statistically significant differences in bleeding rates, specifically in severe or clinically relevant non-major bleeding events.
Importantly, the efficacy in preventing clot recurrence appears comparable between the two drugs, meaning Eliquis isn't just safer, it's equally effective.
For Ottawa Patients
If you or a family member is currently on anticoagulation therapy for DVT or another clot condition, this study is worth discussing with your physician at your next appointment. Drug choices in this category are always about weighing individual risk factors, but new data can and should inform those conversations.
Source: CBC News
